![]() ![]() 1,2 While remote cardiac monitoring has improved arrhythmia detection, patient compliance and timely access to heart activity currently limit accurate and timely diagnosis. ![]() Heart arrhythmias are a major health concern that doubles the risk of death in an estimated 33.5 million people worldwide. RhythmStar is now available with HeartTime™ on-demand telemetry mode, an innovative platform that allows physicians to evaluate cardiac activity and expedite care via a telemedicine appointment, limiting the need for an in-person office visit. The technology enables rapid ECG analysis and reporting of cardiac abnormalities by RhythMedix's team of US-based certified technicians, who alert physicians if an arrhythmia of concern is detected. The novel cardiac telemetry monitor is discreetly worn for extended remote monitoring without the need for an additional phone or communication device. 18, 2021 /PRNewswire/ - RhythMedix, a leader in remote cardiac monitoring, today announced the release of its next-generation RhythmStar ® wearable device with built-in 4G cellular connectivity. Subsequently, the market for devices to treat heart arrhythmias (such as electrophysiology ablation devices or pacemakers) will grow.MOUNT LAUREL, N.J., Feb. ![]() Overall, if more people are able to diagnose their heart arrhythmias earlier thanks to wearable devices, the pool of patients requiring treatment for their arrhythmias will increase. This streamlined approach to wearable ECG monitoring may entice more people to use these types of devices, raising their market potential. This means that the device itself can collect ECG recordings and send them wirelessly to physicians without the need for an intermediate device such as a phone. The RhythmStar cardiac monitor, a new wearable ECG monitoring device from RhythMedix, has built-in cellular connectivity. Typically, the ECG recordings from these devices are sent to a nearby cellular device such as a smart phone, where an application collects and reads the ECG recordings and, in some cases, transmits them to physicians wirelessly. On the other hand, some devices are manufactured specifically for this purpose, such as AliveCor’s Kardia device. This capability has even been incorporated into more generic devices for instance, Apple’s SmartWatch has been FDA-approved to take clinical-grade ECG recordings and detect atrial fibrillation. There are a number of wearable devices that detect heart arrhythmias via electrocardiogram (ECG) monitoring. It is important to diagnose and treat heart arrhythmias early because, if left untreated, they can lead to heart failure or, in some cases, even sudden cardiac death. Heart rhythm issues, or “arrhythmias,” may affect as many as 2% of adults.Īs of 2021, GlobalData estimates that atrial fibrillation (a specific type of arrhythmia) affects nearly four million Americans. In the cardiology space, a common application for wearable technology is heart rhythm monitoring. While historically utilised mainly for fitness tracking, the usage of wearable technology has been steadily growing in the healthcare field. In healthcare, “wearable technologies” refers to non-invasive devices that capture, analyse, and aggregate physiological data to improve personal health and well-being. This device boasts cellular connectivity and joins a roster of wearable cardiac devices already available on the market. On 18 February 2021, RhythMedix announced the launch of its newest-generation wearable cardiac monitor, the RhythmStar. ![]()
0 Comments
Leave a Reply. |